REVA Initiates Commercial Distribution Partnership in Turkey

San Diego, California, UNITED STATES

SAN DIEGO, April 02, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced that it will initiate commercial operations in the Republic of Turkey working in partnership with Kardionet HealthCare and Foreign Trading, Ltd (“Kardionet”). This partnership is REVA’s first commercial distribution agreement in the Europe and Middle East region, building on direct-selling commercial efforts underway in Europe.

“We are very excited to bring the Fantom® bioresorbable scaffold to patients in Turkey. We believe that it will be well received by physicians, who have experience with first generation bioresorbable scaffolds and have expressed interest in Fantom’s x-ray visibility, thinner strut profile, and improved ease-of-use,” said Carmelo Mastrandrea, VP Europe, REVA Medical. “Kardionet’s proven success with interventional cardiology devices and their demonstrated support of patients and physicians make them an ideal distributor for us in Turkey.”

Under the terms of the agreement, Kardionet will be REVA’s distribution partner for the Fantom and Fantom Encore bioresorbable scaffolds in the Republic of Turkey. Kardionet will be responsible for all sales, marketing, customer training, and support. Commercialization is expected to begin with Fantom in the second quarter of 2018, following local registration approval and successful completion of REVA’s training program by Kardionet personnel.

“REVA’s top corporate priority is ensuring Fantom’s commercial success. We began our first phase of launch with our direct sales force in Germany, Switzerland, and Austria last year. The distribution agreement with Kardionet marks the start of our second phase of launch for Fantom,” said Reggie Groves, CEO, REVA Medical. “Physician interest in Fantom continues to be strong. We expect distribution partnerships to complement our direct-selling efforts as we expand commercial activities for Fantom.”

About Fantom and Fantom Encore
Fantom and Fantom Encore are sirolimus-eluting bioresorbable scaffolds developed as an alternative to metallic stents for the treatment of coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, and then disappear (or “resorb”) from the body over a period of time. This resorption is intended to allow the return of natural movement and function of the artery. Fantom and Fantom Encore are the only bioresorbable scaffolds made from Tyrocore, REVA’s proprietary tyrosine-derived polymer designed specifically for vascular scaffold applications. Tyrocore is inherently radiopaque, making Fantom and Fantom Encore the first and only bioresorbable scaffolds that are visible under fluoroscopy. Fantom and Fantom Encore are designed with thin struts while maintaining strength and with distinct ease-of-use features such as expansion with one continuous inflation.

About REVA Medical
REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s lead products are the Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease. REVA is located in San Diego, California, USA and employs over 50 people in the U.S. and Europe.

Fantom, Fantom Encore, and Tyrocore are trademarks of REVA Medical, Inc.

Forward-Looking Statements
This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating plans or performance and events or developments that may occur in the future, are forward-looking statements, such as those statements regarding the projections and timing surrounding commercial operations and sales, clinical trials, pipeline product development, and future financings. No undue reliance should be placed on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the “SEC”) on March 7, 2018, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

 United StatesAustraliaAustralia
 Investor & Media Enquiries:Investor Enquiries:Media Enquiries:
 REVA Medical, Inc.Inteq LimitedBuchan Consulting
 Brandi RobertsKim JacobsRebecca Wilson
 Chief Financial Officer+61 438 217 279+61 3 9866 4722
 +1 858-966-3003Andrew Cohen 
 Cheryl Liberatore+61 408 333 452 
 Director, Communications  
 +1 858-966-3045